Abstract: As a vital component of traditional Chinese medicine, proprietary Chinese medicines have to be properly selected to ensure rational clinical use. Based on the conventional evaluation of safety, effectiveness, economy, innovation, suitability, and accessibility, the incorporation of the “heritability” dimension, which shows the distinct features of traditional Chinese medicine, has resulted in a “6+1” selection framework that has become a widely-used approach to evaluating the clinical value of proprietary Chinese medicines. This paper is intended to interpret the core connotations of each dimension within the “6+1” selection framework, analyze the challenges to its practical applications, and recommend ways of implementation from a unique perspective. A dynamic weighting mechanism is proposed that can flexibly adjust weights based on such factors as disease profiles, stages of treatment, and health care policies so that a gateway to decision-making is grounded on real-world evidence and clinical needs, thereby improving the adaptability and applicability of the evaluation framework. This study is expected to offer a reference for optimizing drug directories in medical institutions, improving the quality of TCM services, and for formulating better guidelines.

Key words: Proprietary Chinese Medicines, Comprehensive Evaluation, Clinical Needs, Dynamic Weighting